Multi-Marker Panel for Early Liver Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for detecting hepatocellular carcinoma (HCC) have limitations in specificity and sensitivity, particularly for early detection in asymptomatic patients, with existing markers like AFP showing low sensitivity and specificity, necessitating the development of more accurate diagnostic tools.
Innovation Solution
The use of biomarkers such as ACADVL, ANLN, BASP1, MTHFD1, CAPN1, C4A, FLNB, and PABPC1, either alone or in combination, for non-invasive detection of HCC, which can be analyzed using various methods including ELISA kits, microarrays, and mass spectrometry, to improve diagnostic accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If AFP is used as a biomarker for HCC diagnosis, then the diagnostic method is simple and widely available, but the sensitivity and specificity are low
Solution Approach 1:
The patent combines multiple biomarkers (AFP, PIVKA-II, DCP, GPC-3, and other liver cancer-specific markers) into a multi-marker panel system. This merging approach allows the diagnostic system to maintain the ease of detection associated with individual markers like AFP while significantly improving diagnostic accuracy through the complementary information provided by multiple markers, thereby resolving the contradiction between simplicity and precision.
Solution Approach 2:
The invention creates a composite diagnostic approach by integrating multiple biomarker types (proteins, glycoproteins, and other molecular markers) into a unified diagnostic panel. This composite strategy leverages the strengths of different marker types to achieve high sensitivity and specificity while maintaining practical detectability, thus overcoming the limitations of single-marker systems.
2Measurement precision
If the AFP threshold is lowered to 20 ng/mL to increase sensitivity, then more HCC cases are detected, but the specificity decreases to 60%
Solution Approach 1:
The patent segments the diagnostic evaluation into multiple independent biomarker assessments rather than relying on a single AFP threshold. Each biomarker in the panel (AFP, PIVKA-II, DCP, GPC-3, etc.) contributes separately to the overall diagnostic decision, allowing the system to achieve high sensitivity through multiple detection opportunities while maintaining high specificity by requiring consistent positive findings across multiple markers, thus resolving the sensitivity-specificity trade-off.
3Measurement precision
If multiple biomarkers are used in combination to improve diagnostic accuracy, then sensitivity and specificity increase, but the complexity of the diagnostic system increases
Solution Approach 1:
The patent develops a multi-functional biomarker panel where a single diagnostic system evaluates multiple biomarkers simultaneously. This universal approach allows the same diagnostic platform to detect various types of liver cancer through different markers, achieving high diagnostic accuracy across diverse HCC cases without requiring separate complex systems for each marker, thus managing complexity while improving accuracy.
Data Source
Figure 1~2A
Figure 2B
Figure 2C~2D
AI summary
The present invention relates to a biomarker for diagnosis or prognosis of liver cancer which is at least one member selected from the group consisting of ACADVL, ANLN, BASP1, MTHFD1, CAPN1, C4A, FLNB and PABPC1, and a measurement kit, a composition and a method which are for diagnosis or prognosis of liver cancer which include the same. The biomarker according to the present disclosure enables, with high accuracy and sensitivity, an early diagnosis of or monitoring of hepatocellular carcinoma and effective prognosis or assessment of progression of disease. In addition, simple and effective diagnosis of or monitoting of liver cancer is possible by noninvasive tests using blood, urine or the like, and thus the present invention will be very effective in the early detection of liver cancer at home or general clinic through a development of, for example, point of care testing (POCT).